Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Expert Review of Vaccines

• Publication date

  2016-06-13

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1080/14760584.2016.1194759PMID 27267297PMCID PMC5156833
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Poliovirus vaccine inactivated

  2018cited by this paper
• The Neutralizing Face of Hepatitis C Virus E2 Envelope Glycoprotein

  2018cited by this paper
• Hepatitis C Virus

  2016cited by this paper
• Apolipoprotein E Mediates Evasion From Hepatitis C Virus Neutralizing Antibodies.

  2016cited by this paper
• The candidate

  2016cited by this paper
• Hepatitis C reinfection after sustained virological response.

  2016cited by this paper
• Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.

  2016cited by this paper
• Virus-Specific CD4+ T Cells Have Functional and Phenotypic Characteristics of Follicular T-Helper Cells in Patients With Acute and Chronic HCV Infections.

  2016cited by this paper
• The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments

  2015cited by this paper
• Monoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable Region

  2015cited by this paper
• Clearance of persistent hepatitis C virus infection using a claudin-1-targeting monoclonal antibody

  2015cited by this paper
• Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design

  2015cited by this paper
• Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus

  2015cited by this paper
• T cell responses in hepatitis C virus infection: historical overview and goals for future research.

  2015cited by this paper
• Global control of hepatitis C virus

  2015cited by this paper
• HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice

  2015cited by this paper
• Hepatitis C virus infects rhesus macaque hepatocytes and simianized mice

  2015cited by this paper
• Recombinant Hepatitis C Virus Envelope Glycoprotein Vaccine Elicits Antibodies Targeting Multiple Epitopes on the Envelope Glycoproteins Associated with Broad Cross-Neutralization

  2014cited by this paper
• A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing.

  2014influential reference
• Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses

  2014cited by this paper
• Hepatitis C drugs not reaching poor

  2014cited by this paper
• Structure of the Core Ectodomain of the Hepatitis C Virus Envelope Glycoprotein 2

  2014cited by this paper
• Will There Be a Vaccine to Prevent HCV Infection?

  2014cited by this paper
• Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry

  2014cited by this paper
• Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting Antiviral Agents

  2014cited by this paper
• Unraveling hepatitis C virus structure

  2014cited by this paper
• Therapy of hepatitis C--back to the future.

  2014cited by this paper
• The past, present and future of neutralizing antibodies for hepatitis C virus

  2014cited by this paper
• Non-random Escape Pathways from a Broadly Neutralizing Human Monoclonal Antibody Map to a Highly Conserved Region on the Hepatitis C Virus E2 Glycoprotein Encompassing Amino Acids 412–423

  2014cited by this paper
• Curing chronic hepatitis C--the arc of a medical triumph.

  2014cited by this paper
• Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice.

  2013cited by this paper
• A Novel Monoclonal Anti-CD81 Antibody Produced by Genetic Immunization Efficiently Inhibits Hepatitis C Virus Cell-Cell Transmission

  2013cited by this paper
• Hepatitis C Virus E2 Envelope Glycoprotein Core Structure

  2013cited by this paper
• Epidemiology and natural history of HCV infection

  2013influential reference
• Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine

  2013cited by this paper
• Structural Basis of HCV Neutralization by Human Monoclonal Antibodies Resistant to Viral Neutralization Escape

  2013cited by this paper
• 16 – Human papillomavirus vaccines

  2013cited by this paper
• Current progress in development of hepatitis C virus vaccines

  2013cited by this paper
• 27 – Poliovirus vaccine—inactivated

  2013cited by this paper
• HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFNα2a and Ribavirin: a randomized controlled trial

  2013influential reference
• Hepatitis C virus entry.

  2013cited by this paper
• A Hepatitis C Virus (HCV) Vaccine Comprising Envelope Glycoproteins gpE1/gpE2 Derived from a Single Isolate Elicits Broad Cross-Genotype Neutralizing Antibodies in Humans

  2013cited by this paper
• Designing tomorrow's vaccines.

  2013cited by this paper
• Human Monoclonal Antibody MBL‐HCV1 Delays HCV Viral Rebound Following Liver Transplantation: A Randomized Controlled Study

  2013cited by this paper
• 15 – Hepatitis B vaccines

  2013cited by this paper
• Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies.

  2013cited by this paper
• Immune responses to hepatitis C virus (HCV) infection and the prospects for an effective HCV vaccine or immunotherapies.

  2013cited by this paper
• Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies.

  2012cited by this paper
• Cooperativity in Virus Neutralization by Human Monoclonal Antibodies to Two Adjacent Regions Located at the Amino Terminus of Hepatitis C Virus E2 Glycoprotein

  2012cited by this paper
• Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1

  2012cited by this paper
• Prospects for prophylactic and therapeutic vaccines against hepatitis C virus.

  2012cited by this paper
• Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion.

  2012cited by this paper
• Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus

  2012influential reference
• A Human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo

  2012cited by this paper
• Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

  2012cited by this paper
• Human Monoclonal Antibodies to a Novel Cluster of Conformational Epitopes on HCV E2 with Resistance to Neutralization Escape in a Genotype 2a Isolate

  2012cited by this paper
• Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus.

  2012cited by this paper
• Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains.

  2011cited by this paper
• Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses

  2011cited by this paper
• Clearance of Genotype 1b Hepatitis C Virus in Chimpanzees in the Presence of Vaccine-Induced E1-Neutralizing Antibodies

  2011cited by this paper
• Neutralizing Monoclonal Antibodies against Hepatitis C Virus E2 Protein Bind Discontinuous Epitopes and Inhibit Infection at a Postattachment Step

  2011cited by this paper
• Vaccination for hepatitis C virus: closing in on an evasive target

  2011cited by this paper
• Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus.

  2011cited by this paper
• with homologous

  2011cited by this paper
• A Prime-Boost Strategy Using Virus-Like Particles Pseudotyped for HCV Proteins Triggers Broadly Neutralizing Antibodies in Macaques

  2011cited by this paper
• Murine neutralizing antibody response and toxicity to synthetic peptides derived from E1 and E2 proteins of hepatitis C virus.

  2010cited by this paper
• Neutralizing Antibody-Resistant Hepatitis C Virus Cell-to-Cell Transmission

  2010cited by this paper
• Mutations within a Conserved Region of the Hepatitis C Virus E2 Glycoprotein That Influence Virus-Receptor Interactions and Sensitivity to Neutralizing Antibodies

  2010cited by this paper
• Role of N-Linked Glycans in the Functions of Hepatitis C Virus Envelope Proteins Incorporated into Infectious Virions

  2010cited by this paper
• Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation

  2010cited by this paper
• Practically Useful: What the Rosetta Protein Modeling Suite Can Do for You

  2010cited by this paper
• Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults.

  2010cited by this paper
• Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection.

  2010cited by this paper
• Association of anti‐E1E2 antibodies with spontaneous recovery or sustained viral response to therapy in patients infected with hepatitis C virus

  2010cited by this paper
• Hepatitis C Virus Hypervariable Region 1 Modulates Receptor Interactions, Conceals the CD81 Binding Site, and Protects Conserved Neutralizing Epitopes

  2010cited by this paper
• Hypervariable Region 1 Differentially Impacts Viability of Hepatitis C Virus Strains of Genotypes 1 to 6 and Impairs Virus Neutralization

  2010cited by this paper
• Mutations in Hepatitis C Virus E2 Located outside the CD81 Binding Sites Lead to Escape from Broadly Neutralizing Antibodies but Compromise Virus Infectivity

  2009cited by this paper
• Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence.

  2009cited by this paper
• Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus.

  2009cited by this paper
• Hepatitis C Virus (HCV) Infection May Elicit Neutralizing Antibodies Targeting Epitopes Conserved in All Viral Genotypes

  2009cited by this paper
• Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users.

  2009cited by this paper
• Immunogenicity of CIGB‐230, a therapeutic DNA vaccine preparation, in HCV‐chronically infected individuals in a Phase I clinical trial

  2009influential reference
• Chimeric hepatitis B and C viruses envelope proteins can form subviral particles: implications for the design of new vaccine strategies.

  2009cited by this paper
• Definition of a Conserved Immunodominant Domain on Hepatitis C Virus E2 Glycoprotein by Neutralizing Human Monoclonal Antibodies

  2008influential reference
• University of Birmingham Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies

  2008cited by this paper
• Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge

  2008cited by this paper
• Hepatitis C Virus Envelope Glycoprotein E2 Glycans Modulate Entry, CD81 Binding, and Neutralization

  2007cited by this paper
• Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees

  2007cited by this paper
• The Neutralizing Activity of Anti-Hepatitis C Virus Antibodies Is Modulated by Specific Glycans on the E2 Envelope Protein

  2007cited by this paper
• Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo.

  2007cited by this paper
• Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C

  2007cited by this paper
• Hepatitis C virus cell‐cell transmission in hepatoma cells in the presence of neutralizing antibodies

  2007cited by this paper
• Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33.

  2007cited by this paper
• Outcome of acute hepatitis C is related to virus‐specific CD4 function and maturation of antiviral memory CD8 responses

  2006cited by this paper
• Identification of Conserved Residues in the E2 Envelope Glycoprotein of the Hepatitis C Virus That Are Critical for CD81 Binding

  2006influential reference
• Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee

  2005cited by this paper
• Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada.

  2005cited by this paper
• GlyProt: in silico glycosylation of proteins

  2005cited by this paper
• Monoclonal Antibody AP33 Defines a Broadly Neutralizing Epitope on the Hepatitis C Virus E2 Envelope Glycoprotein

  2005cited by this paper
• Analysis of a Highly Flexible Conformational Immunogenic Domain A in Hepatitis C Virus E2

  2005cited by this paper

• Native-like soluble E1E2 glycoprotein heterodimers on self-assembling protein nanoparticles for hepatitis C virus vaccine design.

  2026cites this paper
• Detection of B-Cell Epitopes of Hepatitis C Virus Envelope Proteins Associated with Viral Elimination

  2026cites this paper
• Native-like soluble E1E2 glycoprotein heterodimers on self-assembling protein nanoparticles for hepatitis C virus vaccine design

  2025cites this paper
• Immunogenicity study of a Novel DNA-Based HCV vaccine candidate.

  2024cites this paper
• Hepatitis C Virus E1E2 Structure, Diversity, and Implications for Vaccine Development

  2024cites this paper
• In silico design of a novel multi-epitope vaccine against HCV infection through immunoinformatics approaches.

  2024cites this paper
• A Synopsis of Hepatitis C Virus Treatments and Future Perspectives

  2023cites this paper
• Structure of engineered hepatitis C virus E1E2 ectodomain in complex with neutralizing antibodies

  2023cites this paper
• Prospects for developing an Hepatitis C virus E1E2‐based nanoparticle vaccine

  2023cites this paper
• High-Titer Hepatitis C Virus Production in a Scalable Single-Use High Cell Density Bioreactor

  2022cites this paper
• Advances in Tumor Antigen‐Based Anticancer Immunotherapy: Recent Progress, Prevailing Challenges, and Future Perspective

  2022cites this paper
• Two-component vaccine consisting of virus-like particles displaying hepatitis C virus envelope protein 2 oligomers

  2022cites this paper
• Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective

  2022cites this paper
• Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice.

  2022cites this paper
• Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH

  2021cites this paper
• In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet?

  2021cites this paper
• Viral hepatitis update: Progress and perspectives

  2021cites this paper
• SARS-CoV-2 Production in a Scalable High Cell Density Bioreactor

  2021cites this paper
• Hepatitis C Virus Glycan-Dependent Interactions and the Potential for Novel Preventative Strategies

  2021cites this paper
• The next generation of HCV vaccines: a focus on novel adjuvant development

  2021cites this paper
• Structural and Biophysical Characterization of the HCV E1E2 Heterodimer for Vaccine Development

  2021cites this paper
• Structure-Based and Rational Design of a Hepatitis C Virus Vaccine

  2021cites this paper
• Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH.

  2021influential citation
• Design of a native-like secreted form of the hepatitis C virus E1E2 heterodimer

  2021cites this paper
• HCV Core/NS3 Protein Immunization with “N-Terminal Heat Shock gp96 Protein (rNT (gp96))” Induced Strong and Sustained Th1-Type Cytokines in Immunized Mice

  2021cites this paper
• Specific Antibodies Induced by Immunization with Hepatitis B Virus-Like Particles Carrying Hepatitis C Virus Envelope Glycoprotein 2 Epitopes Show Differential Neutralization Efficiency

  2020cites this paper
• Junctional and somatic hypermutation-induced CX4C motif is critical for the recognition of a highly conserved epitope on HCV E2 by a human broadly neutralizing antibody

  2020cites this paper
• Enhancing the antigenicity and immunogenicity of monomeric forms of hepatitis C virus E2 for use as a preventive vaccine

  2020cites this paper
• Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization

  2020cites this paper
• Supramolecular assembly of Toll-like receptor 7/8 agonist into multimeric water-soluble constructs enables superior immune stimulation in vitro and in vivo.

  2020cites this paper
• Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines

  2020cites this paper
• In Vivo and In Vitro Potency of Polyphosphazene Immunoadjuvants with Hepatitis C Virus Antigen and the Role of Their Supramolecular Assembly.

  2020cites this paper
• Innate Immune Response against Hepatitis C Virus: Targets for Vaccine Adjuvants

  2020cites this paper
• Hepatitis C virus vaccine design: focus on the humoral immune response

  2020cites this paper
• HCV Glycoprotein Structure and Implications for B-Cell Vaccine Development

  2020cites this paper
• Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine

  2020cites this paper
• Prevention of Hepatitis C Virus Infection and Liver Cancer.

  2020cites this paper
• Hepatitis C Virus Infection: Host–Virus Interaction and Mechanisms of Viral Persistence

  2019cites this paper
• Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery

  2019cites this paper
• Rational design of hepatitis C virus E2 core nanoparticle vaccines

  2019cites this paper
• Current Progress and Challenges in the Development of a Hepatitis C Virus Vaccine

  2019cites this paper
• Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants.

  2019cites this paper
• Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms

  2018cites this paper
• Hepatitis C Virus–Escape Studies for Human Monoclonal Antibody AR4A Reveal Isolate-Specific Resistance and a High Barrier to Resistance

  2018cites this paper
• Immunogenetic and structural analysis of a class of HCV broadly neutralizing antibodies and their precursors

  2018cites this paper
• Conformational Flexibility in the CD81-Binding Site of the Hepatitis C Virus Glycoprotein E2

  2018cites this paper
• Computational Modeling of Hepatitis C Virus Envelope Glycoprotein Structure and Recognition

  2018cites this paper
• Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine

  2018cites this paper
• Designing a B Cell-Based Vaccine against a Highly Variable Hepatitis C Virus

  2018influential citation
• Research gaps in viral hepatitis

  2018cites this paper
• Association of HCV mutated proteins and host SNPs in the development of hepatocellular carcinoma.

  2018cites this paper
• Antibody Responses to a Quadrivalent Hepatitis C Viral-Like Particle Vaccine Adjuvanted with Toll-Like Receptor 2 Agonists

  2018cites this paper
• Hepatitis C Vaccine Development in the Era of Direct‐Acting Antivirals

  2018cites this paper
• Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.

  2017cites this paper
• Virology , Pathogenesis , and Clinical Course HCV is an enveloped , positive-sense , single-stranded RNAvirus of the

  2017cites this paper
• Novel methods to prevent HCV transmission

  2017cites this paper
• Hepatitis B, C, and Delta—Updates in Screening and Infection Prevention Opportunities for Eradication

  2017cites this paper
• Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct-Acting Antiviral Era

  2017cites this paper
• Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals

  2017cites this paper
• Designing an HCV vaccine: a unique convergence of prevention and therapy?

  2017cites this paper
• The Rationale for a Preventative HCV Virus-Like Particle (VLP) Vaccine

  2017influential citation
• Viral evasion and challenges of hepatitis C virus vaccine development.

  2016cites this paper